COMPARISON BETWEEN TOPICAL APPLICATION OF TRANEXAMIC ACID AND ERYTHROMYCIN IN THE TREATMENT OF ROSACEA
Gulala Ibrahim Qader a
a Department of Pharmacology, College of Medicine, University of Sulaimani, Kurdistan Region, Iraq.
Submitted: 25/8/2020; Accepted: 25/2/2021; Published: 21/6/2021
DOI Link: https://doi.org/10.17656/jsmc.10300
Rosacea is a common, chronic relapsing disease, characterized by erythema, telangiectasias, inflammatory papule, and pustule mainly on the mid-face for which many therapies may exist but with limited efficacy. Tranexamic acid is an anti-fibrinolytic drug that acts by inhibiting the action of plasmin and is mainly used to reduce bleeding. Erythromycin is one of the macrolide antibiotics that acts by inhibiting bacterial protein synthesis and in addition to this action it has an immune modulatory effect.
To evaluate the effects of tranexamic acid solution in the treatment of rosacea and compare it with erythromycin gel.
In this study, thirty (30) patients were included, twenty-three patients were women and 7 of them were men, their ages ranged between 28-50 years old with signs and symptoms of rosacea. The patients were grouped into 2 groups; the first group was treated with a derma pen simultaneously with a tranexamic acid solution (Transamin inj/sol 500 mg/5ml) topical application followed by infused wet dressing for 15 minutes, every 7 days for five (5) sessions. The second group was treated with erythromycin gel twice daily for 5 weeks.
At the end of the study all the patients were improved, the improvement was outlined according to the investigator Global Assessment of Rosacea Severity Score (IGA-RSS) and the use of clinical photos. There was a statistically significant improvement (2) units IGA-RSS for tranexamic acid group and (2,8) units for erythromycin gel.
A tranexamic acid solution is a safe, simple, and cheap treatment option for rosacea. It is also as effective as an erythromycin antibiotics to relieve the symptoms of rosacea.
Tranexamic acid; Rosacea; Erythromycin.
1. Update on medical therapies. Skin Therapy Lett 2014;19:1–4.
2. Baldwin HE. Diagnosis and treatment of rosacea: State of the art. J Drugs Dermatology 2012;11:725–30.
3. Tan SR, Tope WD. Pulsed dye laser treatment of rosacea improves erythema, symptomatology, and quality of life. J Am Acad Dermatol 2004;51:592–9. https://doi.org/10.1016/j.jaad.2004.04.010.
4. Gether L, Overgaard LK, Egeberg A, Thyssen JP. Incidence and prevalence of rosacea: a systematic review and meta-analysis. Br J Dermatol 2018;179:282–289. https://doi.org/10.1111/bjd.16481.
5. Elewski BE, Draelos Z, Dréno B, Jansen T, Layton A, Picardo M. Rosacea - Global diversity and optimized outcome: Proposed international consensus from the Rosacea international expert group. J Eur Acad Dermatology Venereol 2011;25:188–200. https://doi.org/10.1111/j.1468-3083.2010.03751.x.
6. Demerjian M, Hachem JP, Tschachler E, Denecker G, Declercq W, Vandenabeele P, et al. Acute modulations in permeability barrier function regulate epidermal cornification: Role of caspase-14 and the protease-activated receptor type 2. Am J Pathol 2008;172:86–97. https://doi.org/10.2353/ajpath.2008.070161.
7. Stefansson K, Brattsand M, Roosterman D, Kempkes C, Bocheva G, Steinhoff M, et al. Activation of proteinase-activated receptor-2 by human kallikrein-related peptidases. J Invest Dermatol 2008;128:18–25. https://doi.org/10.1038/sj.jid.5700965.
8. Holmes AD, Steinhoff M. Integrative concepts of rosacea pathophysiology, clinical presentation and new therapeutics. Exp Dermatol 2017;26:659–67. https://doi.org/10.1111/exd.13143.
9. Whitfeld M, Gunasingam N, Leow LJ, Shirato K, Preda V. Staphylococcus epidermidis: A possible role in the pustules of rosacea. J Am Acad Dermatol 2011;64:49–52. https://doi.org/10.1016/j.jaad.2009.12.036.
10. Cap AP, Baer DG, Orman JA, Aden J, Ryan K, Blackbourne LH. Tranexamic acid for trauma patients: A critical review of the literature. J Trauma - Inj Infect Crit Care 2011;71:S9–S14. https://doi.org/10.1097/TA.0b013e31822114af.
11. Sharma YK, Gupta A. Some other serendipitous discoveries in dermatology. Indian J Dermatol 2016;61:95–96. https://doi.org/10.4103/0019-5154.174045.
12. Sadeq OR, Mowais MA. ERYTHROMYCIN: ITS GLYCEMIC EFFECT IN AN INFECTIOUS PATIENTS. Int Res J Pharm 2018;9:25–9. https://doi.org/10.7897/2230-8407.099182.
13. Two AM, Wu W, Gallo RL, Hata TR. Rosacea: Part II. Topical and systemic therapies in the treatment of rosacea. J Am Acad Dermatol 2015;72:761–70. https://doi.org/10.1016/j.jaad.2014.08.027.
14. Tan J, Berg M. Rosacea: Current state of epidemiology. J Am Acad Dermatol 2013;69:S27-s35. https://doi.org/10.1016/j.jaad.2013.04.043.
15. Halioua B, Cribier B, Frey M, Tan J. Feelings of stigmatization in patients with rosacea. J Eur Acad Dermatology Venereol 2017;31:163–8. https://doi.org/10.1111/jdv.13748.
16. Bewley A, Fowler J, Schöfer H, Kerrouche N, Rives V. Erythema of Rosacea Impairs Health-Related Quality of Life: Results of a Meta-analysis. Dermatol Ther (Heidelb) 2016;6:237–47. https://doi.org/10.1007/s13555-016-0106-9.
17. Egeberg A, Hansen PR, Gislason GH, Thyssen JP. Patients with Rosacea Have Increased Risk of Depression and Anxiety Disorders: A Danish Nationwide Cohort Study. Dermatology 2016;232:208–13. https://doi.org/10.1159/000444082.
18. Two AM, Wu W, Gallo RL, Hata TR. Rosacea: Part I. Introduction, categorization, histology, pathogenesis, and risk factors. J Am Acad Dermatol 2015;72:749–58. https://doi.org/10.1016/j.jaad.2014.08.028.
19. Del Rosso JQ, Thiboutot D, Gallo R, Webster G, Tanghetti E, Eichenfield L, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, Part 1: A status report on the disease state, general measures, and adjunctive skin care. Cutis 2013;92:234–40.
20. Draelos ZD. Assessment of skin barrier function in rosacea patients with a novel 1% metronidazole gel. J Drugs Dermatol 2005;4:557–62.
21. Steinhoff M, Buddenkotte J, Aubert J, Sulk M, Novak P, Schwab VD, et al. Clinical, cellular, and molecular aspects in the pathophysiology of rosacea. J Investig Dermatology Symp Proc 2011;15:2–11. https://doi.org/10.1038/jidsymp.2011.7.
22. Lee SE, Jeong SK, Lee SH. Protease and Protease-activated Receptor-2 signaling in the pathogenesis of atopic dermatitis. Yonsei Med J 2010;51:808–22. https://doi.org/10.3349/ymj.2010.51.6.808.
23. Schaller M, Almeida LMC, Bewley A, Cribier B, Dlova NC, Kautz G, et al. Rosacea treatment update: recommendations from the global ROSacea COnsensus (ROSCO) panel. Br J Dermatol 2017;176:465–71. https://doi.org/10.1111/bjd.15173.
24. Powell F. Clinical practice. Rosacea. N Engl J Med 2005;352:793–803. https://doi.org/10.1056/NEJMcp042829.
25. Anzengruber F, Czernielewski J, Conrad C, Feldmeyer L, Yawalkar N, Häusermann P, et al. Swiss S1 guideline for the treatment of rosacea. J Eur Acad Dermatology Venereol 2017;11:768–80. https://doi.org/10.1111/jdv.14349.
26. Yuan C, Wang XM, Yang LJ, Wu PL. Tranexamic acid accelerates skin barrier recovery and upregulates occludin in damaged skin. Int J Dermatol 2014;53:959–65. https://doi.org/10.1111/ijd.12099.
27. Na JI, Choi SY, Yang SH, Choi HR, Kang HY, Park KC. Effect of tranexamic acid on melasma: A clinical trial with histological evaluation. J Eur Acad Dermatology Venereol 2013;27:1035–9. https://doi.org/10.1111/j.1468-3083.2012.04464.x.
© The Authors, published by University of Sulaimani, College of Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.